BioSpace News Archive

Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that it will now report financial results for the first quarter of fiscal year 2023 after the market closes on Tuesday, May 16, 2023.

Lucid Diagnostics Inc. today provided a business update for the Company and presented financial results for the three months ended March 31, 2023.

Clinical Laserthermia Systems Americas, Inc., a leading provider of office-based, focal laser ablation systems for urologists, announced that AVANT Concierge Urology of Winter Garden, FL, has safely treated its first patients with low-to- intermediate risk prostate cancer using its TRANBERG™ Thermal Therapy System.

RedHill Biopharma Ltd., a specialty biopharmaceutical company, announced that it has received a written notification from the Nasdaq Stock Market LLC dated May 9, 2023 indicating that the Company is not in compliance with the minimum Market Value of Publicly Held Shares set forth in the Nasdaq Rules for continued Nasdaq listing.

Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced that management will participate in the William Blair 43rd Annual Growth Stock Conference.

Retractable Technologies, Inc. reports total net sales of $11.0 million for the first three months of 2023 and an operating loss of $2.7 million for the period, as compared to total net sales for the same period last year of $44.7 million and an operating income of $9.7 million.

Eisai Co., Ltd. and Biogen Inc. announced today that Health Canada has accepted a New Drug Submission (NDS) for lecanemab (brand name in the U.S.: LEQEMBI™), an investigational anti-amyloid beta (Aβ) protofibril* antibody, for the treatment of early Alzheimer’s disease (mild cognitive impairment due to Alzheimer’s disease (AD) and mild AD dementia) with confirmed amyloid pathology in the brain.

CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on developing innovative therapies for liver and other chronic diseases, today announced corporate updates and financial results for the first quarter ended March 31, 2023.

Specialty cancer diagnostics company Precipio, Inc., will be hosting its Q1-2023 corporate update call on May 17th at 5:00 PM ET.

Ardelyx, Inc. announced that on May 8, 2023, the compensation committee of the company’s board of directors granted two new non-executive employees options to purchase an aggregate of 46,178 shares of the company’s common stock, and granted five new non-executive employees an aggregate of 52,600 Restricted Stock Units.